Regulation of neuronal function by choline and 4OH-GTS-21 through alpha 7 nicotinic receptors.
A unique feature of alpha7 nicotinic acetylcholine receptor physiology is that, under normal physiological conditions, alpha7 receptors are constantly perfused with their natural selective agonist, choline. Studying neurons of hypothalamic tuberomammillary (TM) nucleus, we show that choline and the selective alpha7 receptor agonist 4OH-GTS-21 can regulate neuronal functions directly, via activation of the native alpha7 receptors, and indirectly, via desensitizing those receptors or transferring them into a state "primed" for desensitization. The direct action produces depolarization and thereby increases the TM neuron spontaneous firing (SF) rate. The regulation of the spontaneous firing rate is robust in a nonphysiological range of choline concentrations >200 microM. However, modest effects persist at concentrations of choline that are likely to be attained perineuronally under some conditions (20-100 microM). At high physiological concentration levels, the indirect choline action reduces or even eliminates the responsiveness of alpha7 receptors and their availability to other strong cholinergic inputs. Similarly to choline, 4OH-GTS-21 increases the TM neuron spontaneous firing rate via activation of alpha7 receptors, and this regulation is robust in the range of clinically relevant concentrations of 4OH-GTS-21. We conclude that factors that regulate choline accumulation in the brain and in experimental slices such as choline uptake, hydrolysis of ACh, membrane phosphatidylcholine catabolism, and solution perfusion rate influence alpha7 nAChR neuronal and synaptic functions, especially under pathological conditions such as stroke, seizures, Alzheimer's disease, and head trauma, when the choline concentration in the CSF is expected to rise.
Uteshev
Vladimir V
VV
Department of Pharmacology and Therapeutics, University of Florida College of Medicine, University of Florida, Gainesville, Florida 32610-0267, USA.
Meyer
Edwin M
EM
Papke
Roger L
RL
D000157:Aconitine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000691:Anabasine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000818:Animals; D002794:Choline / Q000494:pharmacology*; D066298:In Vitro Techniques; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D018733:Nicotinic Antagonists / Q000378:metabolism / Q000494:pharmacology; D018697:Nootropic Agents / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011978:Receptors, Nicotinic / Q000502:physiology*; D014316:Tritium; D064569:alpha7 Nicotinic Acetylcholine Receptor
C116666:3-(4-hydroxy-2-methoxybenzylidene)anabaseine; C579165:Chrna7 protein, rat; D018733:Nicotinic Antagonists; D018697:Nootropic Agents; D011978:Receptors, Nicotinic; D064569:alpha7 Nicotinic Acetylcholine Receptor; D014316:Tritium; C054634:methyllycaconitine; D000691:Anabasine; D002794:Choline; D000157:Aconitine